In consideration for the license, the Company agreed to pay Fidelion a total license fee of $2,000,000 in 24 equal monthly instalments and committed to purchase at least $500,000 in value of VitaGuar…
For three month periods ended March 31, 2026 and 2025, respectively, the suppliers who accounted for 10 % or more of the Company’s cost of sales and their balances at period ended are presented as fo…
For three month periods ended March 31, 2026 and 2025, respectively, the suppliers who accounted for 10 % or more of the Company’s cost of sales and their balances at period ended are presented as fo…
Under the terms of the Purchase Agreement, ARC has committed to purchase, from time to time at the Company’s discretion, up to $500,000,000 of the Company’s common stock, no par value per share ("Com…
For three month periods ended March 31, 2026 and 2025, respectively, the customers who accounted for 10 % or more of the Company’s revenue and their balances at period ended are presented as follows:…
For three month periods ended March 31, 2026 and 2025, respectively, the customers who accounted for 10 % or more of the Company’s revenue and their balances at period ended are presented as follows:…
BioNexus Gene Lab Corp. Debt Obligations
Instrument
Description
Confidence
Evidence
BGLC-DEBT
Debt stack $225,525
90%
Market cache reports total debt of $225,525.
BioNexus Gene Lab Corp. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioNexus Gene Lab Corp..
BioNexus Gene Lab Corp. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for BioNexus Gene Lab Corp..
